In the continuing saga on Valeant, CFO Howard Schiller has been asked to resign. The company will also find the replacement of CEO Michael Pearson, and putting Bill Ackman in its board.
Michael Pearson
Breaking News
Canadian pharmaceutical company shares dropped 18% on Monday, as the company admitted being under investigation by U.S. Securities and Exchange Commission.
Goldman Sachs sold 1.3 million shares from Valeant on Thursday, which the pharmaceuticals company was holding as collateral for its CEO, Michael Pearson.
Subscribe to VCpost newsletter
Most Popular
- SSDI Payment April 2024: Who Will Receive Social Security Benefits Today?
- Brazilian Woman Wheels Her Dead Uncle Into the Bank to Withdraw Loan in His Name
- Trump Media’s First Auditor Quits After Just a Few Months on the Job: Report
- Tesla Spends $200,000 in Promoting Elon Musk's Social Media Platform X Following Mention of 'Minimal Advertising Efforts'
- UPDATE: Google Employees Arrested and Fired After Staging Protests Over Company's Project Nimbus Deal With Israel
- Social Security Benefits: 2025 COLA Predicted to Increase Amid Rising Inflation
- Spirit Airlines Staff at Florida Airport Filmed Cursing a 'Karen' Passenger After Moaning About Her Flight
- Navigating Tariff Tides: A Conversation with Jim Pratt on Supply Chain Strategies Ahead of 2024 Elections
